C12Y 302/02006
Nad+ nucleosidase
Official title: NAD(P)+ nucleosidase (3.2.2.6)
C12Y302/02006 (Nad+ nucleosidase) appears on 2 US grants and 16 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 16
- Assignees
- 18
- Inventors
- 53
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 1 |
| 2023 | 1 | 5 |
| 2024 | 0 | 1 |
| 2025 | 0 | 4 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy21 Aug 2025US 2025/0262300 A1Kite Pharma, Inc.
- Sarm1 rnai agents7 Aug 2025US 2025/0249118 A1Eli Lilly and Company
- Sarm1 rna interference agents12 Jun 2025US 2025/0188472 A1Eli Lilly and Company
- Probiotic vaccines and related methods of use8 May 2025US 2025/0144193 A1Salvitus, Inc.
- Methods for diagnosis and monitoring of toxic epidermal necrolysis4 Jan 2024US 2024/0003879 A1Centre National de la Recherche Scientifique (CNRS)
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.